Cigna CEO David Cordani to Step Down; Brian Evanko Named Successor

Cigna CEO transition announced

Published: March 3, 2026 — Cigna (CI) announced a scheduled CEO transition that sent shares lower in early trading. David Cordani, who has led Cigna since 2009, will step down as chief executive on July 1, 2026, concluding a 17-year tenure as CEO. Cordani is 60.

Brian Evanko, 49, currently president and chief operating officer, will succeed Cordani as CEO on July 1, 2026. Evanko has spent his entire career at Cigna and has been elevated through senior operating roles within the company.

Key facts (quotable, self-contained)

• David Cordani will step down as CEO of Cigna on July 1, 2026, after serving as CEO since 2009.
• Brian Evanko, 49, will take over as CEO on July 1, 2026; he is the company’s president and chief operating officer and is an internal successor.
• Cigna’s stock (CI) declined in early Tuesday trading after the leadership announcement.

What the transition means for investors

The planned internal succession in a major health insurer typically signals continuity in strategy and operations, while also giving investors a timeframe to reassess leadership risk. For institutional investors and traders, the most relevant near-term considerations include:

• Leadership continuity: An internal successor like Evanko generally reduces execution risk tied to strategic changes, since he has worked across Cigna’s operations.
• Market reaction: The initial share slump reflects investor uncertainty common around executive transitions; traders will watch subsequent quarterly results and guidance for confirmation of strategic continuity.
• Governance timeline: With a July 1 effective date, the company provides a clear handover window that allows investors to monitor any interim operational or personnel adjustments.

Analyst and stakeholder focus areas post-announcement

Institutional investors and financial analysts should monitor the following metrics and developments as proxies for management continuity and operational resilience:

• Earnings guidance and margin commentary in the next quarterly report.
• Capital allocation statements, including share repurchase and dividend plans.
• Any changes to executive leadership beyond the CEO role that could indicate strategic shifts.
• Operational indicators such as membership trends, medical cost management, and expense control commentary.

Why an internal successor matters

Promoting Brian Evanko from within suggests the board prioritized stability and institutional knowledge. Internal successions can:

• Preserve existing strategic priorities and multi-year initiatives.
• Maintain institutional relationships with payers, providers and large employer clients.
• Minimize transition-related disruption to operations and strategic programs.

However, investors will still evaluate Evanko on his ability to deliver measurable results against Cigna’s financial and operational targets.

Risk considerations

• Short-term volatility: Leadership changes often trigger near-term stock volatility as market participants price in uncertainty.
• Execution scrutiny: Even internal successors must demonstrate that they can translate operational experience into company-wide strategic execution.
• Regulatory and public scrutiny: The broader health insurance sector faces heightened scrutiny, and leadership changes can draw added attention from stakeholders and policymakers.

What to watch next (timeline)

• Immediate: Management and investor calls following quarterly filings; any additional detail on strategic priorities from Evanko.
• Next 90 days: Investor presentations, quarterly earnings and guidance updates that reveal whether strategy and capital allocation will remain consistent.
• Through July 1, 2026: Handover progress and any announced changes to the executive leadership team.

Bottom line

The announced transition on March 3, 2026 positions Cigna (CI) for a planned, internal leadership change effective July 1, 2026. David Cordani will step down after 17 years as CEO; Brian Evanko, 49 and currently president and COO, will succeed him. For professional traders and institutional investors, the key questions are whether the internal succession preserves strategic continuity and how quickly investors receive measurable confirmation through earnings, guidance and capital-allocation actions.

Quick reference

• Company: Cigna (CI)
• Outgoing CEO: David Cordani (CEO since 2009; will step down July 1, 2026; age 60)
• Incoming CEO: Brian Evanko (President & COO; will become CEO July 1, 2026; age 49)
• Market reaction: Shares slumped in early Tuesday trading after the announcement